전체메뉴

Journal of Pharmacopuncture

Article Search

JoP

Best Practice

Compliance of Journal of Pharmacopuncture to the Principles of transparency and best practice in scholarly publishing
(joint statement by COPE, DOAJ, WAME, and OASPA;- http://doaj.org/bestpractice)

Enacted March 19, 2020

  • 1. Website:
    • i. The URL address of official journal web site: https://www.journal-jop.org
      ii. ‘Aims & Scope’ statement:

      Aims
      The Journal of Pharmacopuncture is an international, peer-reviewed open-access journal published in English by the Korean Pharmacopuncture Institute (KPI). The journal has provided high-quality papers quarterly since it was launched in 1997. Its ISSN was changed in September 2010
      from 1226-4849 to 2093-6966 when its title was changed from Daehanyakchimhakhweiji to the Journal of Pharmacopuncture. The journal aims to publish evidence-based, scientific research papers in the multidisciplinary field of traditional and modern medicine through a strict review process by a panel of experts. As an international journal, the Journal of Pharmacopuncture also aims to present major advances and new developments contributing to the advancement of complementary and alternative medicine, with a special focus on pharmacology, acupuncture and a combination of pharmacology and acupuncture. The journal is dedicated to disseminating current data and ideas and fostering debate on issues related to complementary and alternative medicine and to providing better information to both the general public and experts. In addition, the journal requires high standards of research ethics to maintain the integrity of science. The official title of the journal is 'Journal of Pharmacopuncture', and the abbreviated title is 'J. Pharmacopunct.' For submission, see the details at http://www.journal-jop.org

      Scope
      The Journal of Pharmacopuncture covers a wide range of basic and clinical science research relevant to all aspects of the biotechnology of integrated approaches using both pharmacology and acupuncture therapeutics, including research involving pharmacology, acupuncture studies and pharmacopuncture studies. The subjects are mainly divided into three categories: pharmacology (applied phytomedicine, plant sciences, pharmacology, toxicology, medicinal plants, traditional medicines, herbal medicine, Sasang constitutional medicine, herbal formulae, foods, agricultural technologies, naturopathy, etc.), acupuncture (acupressure, electroacupuncture, laser acupuncture, moxibustion, cupping, etc.), and pharmacopuncture (aqua-acupuncture, meridian pharmacopuncture, eight-principles pharmacopuncture, animal-based pharmacopuncture, mountain ginseng pharmacopuncture, bee venom therapy, needle embedding therapy, implant therapy, etc.). Other categories include chuna treatment, veterinary acupuncture and related animal studies, alternative medicines for treating cancer and cancer-related symptoms, etc. Broader topical coverage on the effects of acupuncture, the medical plants used in traditional and alternative medicine, pharmacological action and other related modalities, such as anthroposophy, homeopathy, ayurveda, bioelectromagnetic therapy, chiropractic, neural therapy and meditation, can be considered to be within the journal's scope if based on acupoints and meridians.
      iii. Readership: JoP is primarily for medical researchers and clinicians of acupuncture, traditional medicine, integrative medicine, complementary and alternative medicine, and other personnel who work in the field of medicine. Its readership can be expanded to other positions related to subjects described in aims and scope.
      iv. Authorship criteria: The authorship should be given according to 1) making substantial contribution to the conception and design of the study, or acquisition, interpretation and analysis of data; 2) drafting the article or revising it critically for the important intellectual content; and 3) final approval of the version to be published. When a large, multicenter group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. When submitting a manuscript authored by a group, the corresponding author should clearly indicate the preferred citation and identify all individual authors as well as the group name. Journals generally list other members of the group in the Acknowledgments. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship.
      v. Duplicate submission and redundant publication: Submitted manuscripts must not have been previously published or be under consideration for publication elsewhere. No part of the accepted manuscript should be duplicated in any other scientific journal without the permission of the Editorial Board. Submitted manuscripts are screened for possible plagiarism or duplicate publication by Similarity Check upon arrival. If plagiarism or duplicate publication is detected, the manuscripts may be rejected, the authors will be announced in the journal, and their institutions will be informed. There will also be penalties for the authors. A letter of permission is required for any and all material that has been published previously. It is the responsibility of the author to request permission from the publisher for any material that is being reproduced. This requirement applies to text, figures, and tables.
      vi. pISSN: 2093-6966 eISSN: 2234-6856
  • 2. Name of journal
    • The official title of the journal is 'Journal of Pharmacopuncture', and the abbreviated title is 'J. Pharmacopunct.'
  • 3. Peer review process
    • We adopt the double-blind peer review.

      Reviewers are assigned to a submitted paper for peer review.

      Anything indicating identification of authors is removed from the papers assigned for review. The invited reviewers should give a review of the assigned paper within 15 days after agreeing to do review.

      Reviewers classify the paper as accepted in present form, minor revision (accepted after modest revisions), major revision (reconsidered for acceptance after major changes), and rejected at this stage.

      When the paper is evaluated as minor revision (accepted after modest revisions), the reviewers should specify where should be made corrections. Revised papers are put under a second review by the reviewers or the Editorial Board members to determine whether they are acceptable in revised form.

      When a paper is evaluated as major revision (reconsidered for acceptance after major change), the reviewers should specify where should be made corrections. Revised papers are put under a second review by the reviewers or the Editorial Board members to determine whether they are acceptable in revised form.

      When the paper is rejected at this stage, the reviewers should cite specific reasons as to how the decision was reached.

      Review results will be sent to the authors once the required reviews are completed.

      Reviewers should post review results on the website of the Journal of Pharmacopuncture. Emails from reviewers and authors are considered as digital signatures.
  • 4. Ownership and management
  • 5. Governing body
    • The governing body is the journal’s editorial board.
  • 6. Editorial team and contact information
    • i. Editorial team is available from the Editorial Board page at the front part of the journal.
      ii. Contact information
      Suyeon Jo
      JoP Editorial office
      4F AKOM Building, 91, Heojun-ro, Gangseo-gu, Seoul 07525, Korea, Tel: +82-2-2658-9051, Fax: +82-2-2658-9136, E-mail: kpi-jpharmaco@naver.com
  • 7. Copyright and licensing
    • i. Copyright policy: Published manuscripts become the permanent property of the Korean Pharmacopuncture Institute and may not be published elsewhere in any form without written permission.

      ii. Licensing information: JOP Journals are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge & be non-commercial, they don't have to license their derivative works on the same terms.

      Published Open Access articles are distributed under this Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC). Articles can be read and shared for noncommercial purposes under the following conditions:

      BY: Attribution must be given to the original source (Attribution) NC: Works may not be used for commercial purposes (Noncommercial) JOP Journals use the CC BY-NC to protect the author's work from misuse. For more information about creative commons licences, please see: https://creativecommons.org
  • 8. Author fees
    • Neither page charge, article processing charge (also known as a publication fee) for accepted articles nor submission fee will be applied. It is the platinum open access journal.
  • 9. Process for the identification of and dealing with allegations of research misconduct
    • When the journal faces suspected cases of research and publication misconduct such as redundant (duplicate) publication, plagiarism, fraudulent or fabricated data, changes in authorship, an undisclosed conflict of interest, ethical problems with a submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and so on, the resolution process will follow the flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). The discussion and decision on the suspected cases are carried out by the Editorial Board.
  • 10. Publication ethics
    • i. Journal policies on authorship and contributorship: It is described at the Instructions to authors.
      ii. How the journal will handle complaints and appeals: The policy of the journal is primarily aimed at protecting the authors, reviewers, editors, and the publisher of the journal. If not described below, the process of handling complaints and appeals follows the guidelines of the Committee of Publication Ethics available from: https://publicationethics.org/appeals
      • Who complains or makes an appeal?: Submitters, authors, reviewers, and readers may register complaints and appeals in a variety of cases as follows: falsification, fabrication, plagiarism, duplicate publication, authorship dispute, conflict of interest, ethical treatment of animals, informed consent, bias or unfair/inappropriate competitive acts, copyright, stolen data, defamation, and legal problem. If any individuals or institutions want to inform the cases, they can send a letter to the editor. For the complaints or appeals, concrete data with answers to all factual questions (who, when, where, what, how, why) should be provided.
      • Who is responsible to resolve and handle complaints and appeals?: The Editor, Editorial Board, or Editorial Office is responsible for them.
      • What may be the consequence of remedy?: It depends on the type or degree of misconduct. The consequence of resolution will follow the guidelines of the Committee on Publication Ethics (COPE).
      iii. Journal policies on conflicts of interest / competing interests: It is described at the Instructions to authors.
      iv. Journal policies on data sharing and reproducibility; Open data policy: For clarification on result accuracy and reproducibility of the results, raw data or analysis data will be deposited to a public repository after acceptance of the manuscript. Therefore, the submission of the raw data or analysis data is mandatory. If the data is already a public one, its URL site or sources should be disclosed. If data cannot be publicized, it can be negotiated with the editor. If there are any inquiries on depositing data or waiver of data sharing, the authors should contact the editorial office. Clinical data sharing policy: This journal follows the data sharing policy described in “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors” (https://synapse.koreamed.org/Synapse/Data/PDFData/0063JKMS/jkms-32-1051.pdf). The ICMJE's policy regarding trial registration is explained at http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html.
      If the data sharing plan changes after registration this should be reflected in the statement submitted and published with the manuscript, and updated in the registry record. All of the authors of research articles that deal with interventional clinical trials must submit data sharing plan. Based on the degree of sharing plan, authors should deposit their data after deidentification and report the DOI of the data and the registered site.
      v. Journal's policy on ethical oversight: When the Journal faces suspected cases of research and publication misconduct such as a redundant (duplicate) publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interest, and ethical problem discovered with the submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and other issues, the resolving process will follow the flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). All studies involving human subjects or human data must be reviewed and approved by a responsible Institutional Review Board (IRB). The Editorial Board will discuss the suspected cases and reach a decision. We will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when needed.
      vi. Journal's policy on intellectual property: All published papers become the permanent property of the Korean Pharmacopuncture Institute. Copyrights of all published materials are owned by the Korean Pharmacopuncture Institute.
      vii. Journal's options for post-publication discussions and corrections: The post-publication discussion is available through letter to editor. If any readers have a concern on any articles published, they can submit letter to editor on the articles. If there founds any errors or mistakes in the article, it can be corrected through erratum, corrigenda, or retraction.
  • 11. Publishing schedule
    • It is to be published quarterly. Supplement issues may be published.
  • 12. Access
    • This is an open-access journal distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivative (CC BY-NC) license, which is for non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s).
  • 13. Archiving
  • 14. Revenue sources
    • Revenue sources of journal are from the support of publisher (Korean Pharmacopuncture Institute), Korea Government’s support, and advertising rates.
  • 15. Advertising
    • Journal of Pharmacopuncture accepts any advertisements on the following basis:

      Eligibility of the advertised products or services
      All products or services should be safe and reliable, and not cause any harm to the health and welfare of humans. Advertisements may promote information and technologies relevant for authors, editors, reviewers, and readers. Pharmaceutical products may also be considered.
      - Advertising is separate from content. Advertisers and sponsors have no advance knowledge of our editorial contents, nor do the editors have advance knowledge of advertisers. Content is never altered, added, or deleted to accommodate advertising. Advertisers and sponsors have no input regarding any of our editorial decisions or advertising policies.
      - We reserve the right to decline or cancel any advertisement at any time.
      - Advertisements for pharmaceutical products must conform to all regulations and policies of the Ministry of Food and Drug Safety, Republic of Korea in every respect.

      Orders
      Any individuals or organizations who are interested in advertising their products or services in the print copies of the journal or on its website are encouraged to contact the editorial office. The acceptance of advertisements will be discussed by the editorial board and will be ultimately approved by the publisher.

      Advertisement fee
      For one print copy issue, the advertisement price for one whole page is USD 1,000 (or KRW 1,000,000). If the advertisement is half a page, the price is reduced by half. For a quarter of the page, this price is reduced by one quarter.

      Disclaimer Liability: Neither the publisher nor the editors will be legally liable for advertisements presented in the journal. In addition, they cannot guarantee the accuracy, completeness, or usefulness of the information provided.
      Endorsement: The publisher and the editors do not endorse any products or services that are advertised.
      Disclaimer: Neither the publisher nor the authors will be legally liable for any of the content of advertisements, so readers must keep this in mind when reading or seeing advertisements.
  • 16. Direct marketing
    • Journal propagation has been done through the journal web site and distribution of an introduction pamphlet. Invitations to submit a manuscript are usually focused on the presenters at conferences, seminars, or workshops if the topic is related to the journal's aims and scope.

Journal Info

Journal of Pharmacopuncture
March, 2023
Vol.26 No.1

pISSN 2093-6966
eISSN 2234-6856
Quarterly

Archives >

Editorial Office

Tel
Tel +82-2-2658-9051
Fax
Fax +82-2-2658-9136
E-mail
E-mail kpi-jpharmaco@naver.com

Most Read / Downloaded

  • Original Article2021-06-30
    JoP

    Quality Control of Pharmacopuncture: A Comparative Study of Good Manufacturing Practice and External Herbal Dispensary Standards

    Ji-Eun Han1, Minjung Park2, Tteul-E-Bom An3, Jong-Hyun Park4, Danny Oh5, Kyeong Han Kim6*, Soo-Hyun Sung1*
    J Pharmacopuncture 2021; 24(2): 59-67 https://doi.org/10.3831/KPI.2021.24.2.59

    Abstract : Objectives: We aimed to compare the external herbal dispensary (EHD) evaluation criteria for pharmacopuncture and the Korea Good Manufacturing Practice (KGMP) sterile medicine standards to contribute to the establishment of quality control criteria for pharmacopuncture.Methods: We obtained the KGMP standards from the Ministry of Food and Drug Safety and the pharmacopuncture certification criteria from the Ministry of Health and Welfare of South Korea. The EHD evaluation items were classified into three categories: facilities, quality control, and validation. The evaluation items were compared with the KGMP sterile medicine criteria to determine their conformance with each other, followed by a discussion among the committee of six experts and their consensus to suggest the items to complement the EHD evaluation criteria.Results: Among the KGMP sterile medicine criteria, 44 were related to the management of the facilities, and 32 pharmacopuncture evaluation items corresponded to these KGMP items (66.7%). Fifty-eight KGMP criteria were related to quality management, and 42 pharmacopuncture evaluation items corresponded to these KGMP items (72.4%). Twenty-five KGMP sterile medicine criteria were related to validation, and 11 pharmacopuncture evaluation items corresponded to these KGMP items (44.0%). Sixteen items under the pharmacopuncture EHD criteria corresponded to the KGMP sterile medicine criteria based on the consent of the experts. Among these, 4 were related to facility management, 6 were related to quality control, and 6 were related to validation.Conclusion: For the safety and quality control of pharmacopuncture, there is a need to select the criteria for the mandatory items among the proposed pharmacopuncture-EHD criteria laws and systems to ensure that the pharmacopuncture materials are produced under the pharmacopuncture-EHD in compliance with the relevant requirements. More studies are needed to secure the safety level of pharmacopuncture materials corresponding to that of conventional medicine.

    Abstract
    Full Text PDF Cited By 0 Cite Share
  • Case Report2023-03-31

    Suggested Integrative Approach for Hand Abscess with Cupping Therapy: a case study

    Emad Ahmed Fathy Hussein1*, Shahira Hassan Ibrahim Negm1, Tabish Ishaq Shaikh2, Ahmed Helmy Saleh3
    J Pharmacopuncture 2023; 26(1): 94-98 https://doi.org/10.3831/KPI.2023.26.1.94

    Abstract : A forty-three-year-old male patient was diagnosed with an acute abscess in the dorsum of the right hand. On the 5th day of conventional pharmacological therapy the patient was still suffering, and was referred to the Outpatient department (OPD) to evacuate and drain the abscess and treat the edema around the area with Hijama (wet cupping therapy, WCT). The hand abscess was successfully cured within a week using an integrative approach of wet cupping therapy together with conventional drug therapy.

    Full Text PDF Cited By 0 Cite Share
  • Systematic Review2021-12-31

    Effect of Manual Acupuncture for Mild-to-Moderate Carpal Tunnel Syndrome: A Systematic Review

    Jeong Ho Huh1†, Hye In Jeong2†, Kyeong Han Kim3,4*
    J Pharmacopuncture 2021; 24(4): 153-164 https://doi.org/10.3831/KPI.2021.24.4.153

    Abstract : Objectives: Despite the low cost and high accessibility of manual acupuncture (MA) treatments for the carpal tunnel syndrome (CTS), this intervention has not been uniformly evaluated in systematic reviews (SR), and no SR has evaluated MA monotherapy for CTS. This review was conducted to summarize the findings and undertake a quality assessment of randomized controlled trials (RCTs) of acupuncture treatment methods for mild-tomoderate CTS to identify clinical evidence for the use of MA in CTS.Methods: We searched five databases for articles on relevant RCTs that were published until June 2021 without imposing specific restrictions, such as age or sex, on CTS patients. RCTs that evaluated MA were included without any restriction on comparator interventions. Measurement tools for evaluating pain reduction and functional improvement or for evaluating efficacy using electrophysiological indicators were included as outcome measures.Results: We included seven RCTs, of which three studies reported both post-treatment improvement effects and statistical significance using p-values for all outcomes. Five studies reported statistically significant intergroup differences (p-values for all outcomes) in posttreatment improvement. None of the studies reported severe adverse effects of MA. In all of the RCTs, the reporting rates of the 2c, 2a, and 6a items of STRICTA 2010 were 14%, 29%, and 29%, respectively. PC7 (Daereung) was used to treat CTS in all of the included studies.Conclusion: MA can be used for CTS treatment without serious adverse effects. PC7 was the most commonly used acupoint. In order to ensure objective and reliable reporting, accurate standardization of acupuncture treatment methods acupoint terms should be undertaken in future RCTs.

    Abstract
    Full Text PDF Cited By 0 Cite Share
All Newest Articles
  • Systematic Review2021-06-30

    Effect of Complementary Medicine on Pain Relief and Wound Healing after Cesarean Section: A Systematic Review

    Azin Niazi1, Maryam Moradi2*, Vahid Reza Askari3, Neda Sharifi4
    J Pharmacopuncture 2021; 24(2): 41-53 https://doi.org/10.3831/KPI.2021.24.2.41

    Abstract : Objectives: Cesarean sections are one of the common surgical procedures around the world. Management of cesarean section side effects, including pain, hematoma, delayed wound healing, is of particular importance in maintaining maternal health and ability to care for the baby. The tendency to use complementary medicine strategies is on the rise because of the easy treatment with low side effects. The purpose of this study was to systematically review the efficacy and safety of clinical trials performed in Iran and worldwide on the effect of complementary medicine on pain relief and wound healing after cesarean section.Methods: PRISMA checklist was followed to prepare the report of this systematic review. The search process was carried out on databases on databases of Magiran, SID, Iran Medex, Scopus, Pub Med, Science direct, Medline and Cochrane library using keywords of cesarean, pain, wound healing, Herbal medicine, acupressure, massage, complementary medicine and their Persian equivalent and all possible combinations, from inception until February 2020. We used the Jadad scale to assess the quality of the searched articles. According to the Jadad scale, the articles with a score of at least 3 were included in the study.Results: Finally, 28 clinical trials (with a sample size of 3,245) scored at least 3 on the Jadad scale were included into the analysis. This article reviewed 13 articles on medicinal herbs, 4 articles on massage, 1 article on reflexology, 2 articles on acupressure.Conclusion: According to the present review, the use of medicinal herbs was the most common method of complementary medicine in pain relief and wound healing after cesarean section.

    Abstract
    Full Text PDF Cited By 0 Cite Share
  • Review Article2021-09-30

    Literature Review on Korean Medicine Treatment for Alopecia

    Seul Woo Leem1†, Min Kyeong Kim1†, Seo Lim Ko1, Hye In Jeong2, Kyeong Han Kim3,4*
    J Pharmacopuncture 2021; 24(3): 93-106 https://doi.org/10.3831/KPI.2021.24.3.93

    Abstract : This study aimed to analyze the use of Korean medicine treatments for alopecia in among clinical studies. We identified and analyzed 22 studies from Korean databases; Oriental Medicine Advanced Searching Integrated System (OASIS), Science ON, Korean Studies Information Service System (KISS), and Research Information Sharing Service (RISS) and international database; PubMed. We analyzed the Korean medical treatment in each case and determined the tendency to use each intervention. We analyzed 1,464 patients from 22 selected studies. Herbal medicine, acupuncture, external medicine or products, pharmacopuncture, and phototherapy were used for alopecia treatment. The herbal medicines mainly used to treat alopecia were Gagam Cheongyoung-tang, Gagam Hwajung-hwan, and Yukmijihwang-tang·hwan. The acupoints primarily used were GV20, EX-HN1, GB5, KI3, PC6, ST36, GV22, and A-shi. The most commonly used pharmacopuncture therapies were Hwangryunhaedoktang (HH), Carthami Fructus (CF), Bee Venom (BV), and Hominis placenta (HP). The Korean medical treatment for alopecia improved the condition of patients. However, seven studies reported the occurrence of side effects such as pruritus, dazed, drowsiness, headache, pain, and diarrhea. This study shows the potential of Korean medicine for the treatment of alopecia. Further studies with a large sample size and long-term follow-up are warranted to establish the primary treatment guidelines and objective out-come measures for alopecia.

    Abstract
    Full Text PDF Cited By 0 Cite Share
  • Original Article2021-06-30

    Regulatory Effect of Cannabidiol (CBD) on Decreased β-Catenin Expression in Alopecia Models by Testosterone and PMA Treatment in Dermal Papilla Cells

    Yoon-Jong Park1, Jae-Min Ryu1, Han-Heom Na1,2, Hyun-Suk Jung2,3, Bokhye Kim2, Jin-Sung Park4, Byung-Soo Ahn4,5, Keun-Cheol Kim1,2*
    J Pharmacopuncture 2021; 24(2): 68-75 https://doi.org/10.3831/KPI.2021.24.2.68

    Abstract : Objectives: The hair follicle is composed of more than 20 kinds of cells, and mesoderm derived dermal papilla cells and keratinocytes cooperatively contribute hair growth via Wnt/β-catenin signaling pathway. We are to investigate β-catenin expression and regulatory mechanism by CBD in alopecia hair tissues and dermal papilla cells. Methods: We performed structural and anatomical analyses on alopecia patients derived hair tissues using microscopes. Pharmacological effect of CBD was evaluated by β-catenin expression using RT-PCR and immunostaining experiment. Results: Morphological deformation and loss of cell numbers in hair shaft were observed in alopecia hair tissues. IHC experiment showed that loss of β-catenin expression was shown in inner shaft of the alopecia hair tissues, indicating that β-catenin expression is a key regulatory function during alopecia progression. Consistently, β-catenin expression was decreased in testosterone or PMA treated dermal papilla cells, suggesting that those treatments are referred as a model on molecular mechanism of alopecia using dermal papilla cells. RT-PCR and immunostaining experiments showed that β-catenin expression was decreased in RNA level, as well as decreased β-catenin protein might be resulted from ubiquitination. However, CBD treatment has no changes in gene expression including β-catenin, but the decreased β-catenin expression by testosterone or PMA was restored by CBD pretreatment, suggesting that potential regulatory effect on alopecia induction of testosterone and PMA. Conclusion: CBD might have a modulating function on alopecia caused by hormonal or excess of signaling pathway, and be a promising application for on alopecia treatment.

    Abstract
    Full Text PDF Cited By 0 Cite Share
All Newest Articles

Scimago Journal & Country Rank

SCImago Journal & Country Rank